A new study has revealed that an experimental weight-loss injection, developed by a Chinese company, could rival popular drugs such as Wegovi and Mongaro.
Hot Topics
In a clinical trial, the once-weekly drug ribopatide helped patients lose an average of 17.7% of their body weight in just 11 months—nearly a fifth. Half of the participants who received the highest dose of the drug lost more than a fifth of their original weight.
For comparison, data showed that Wegovi, which contains the active ingredient semaglutide, helped patients lose approximately 18.7% of their weight after 72 weeks, or about 16.5 months. Mongaro, which contains terzepate, achieved a weight loss of approximately 22.5% over the same period.
Although no direct comparison was made between the drugs, the results suggest that "Ribobatide" could become a powerful weight-loss injection that rivals existing treatments on the market.
These results came months after the recruitment of patients in Britain began for Phase 3 trials of the drug.
Ribopeptide works in a similar way to Monjaro, as it mimics two hormones that help regulate appetite and blood sugar, giving a feeling of fullness for a longer period, reducing hunger, and helping to eat less food.
In the study published in JAMA, researchers from Fudan University in Shanghai recruited 567 overweight or obese adults, with an average age of 34, to test the drug. 424 participants received weekly injections of ribobutadec at doses of 2 mg, 4 mg, and 6 mg, while 143 others received a placebo.
After 48 weeks, those who received the lowest dose lost an average of 10.7% of their body weight, compared to 16.4% in the medium dose group and 17.7% in the highest dose group. The placebo group lost only 1.4%.
Some participants also achieved even greater results:
The study indicated that the drug may not have reached its full effect yet, as no clear stabilization in weight loss was shown in the 4 mg and 6 mg groups by week 48.
In addition to weight loss, researchers observed improvements in:
- Blood pressure.
- Controlling blood sugar.
- Cholesterol levels.
- Triglycerides.
Insulin resistance.
Waist circumference.
Systolic blood pressure, the top number in a blood pressure reading, decreased by approximately 7 to 9 points more than in the placebo group. Triglycerides also decreased by 29% to 37% more than in the control group. Insulin resistance decreased by 30% at the 2 mg dose, 44% at the 4 mg dose, and 46% at the 6 mg dose. Total cholesterol decreased by 6% to 9%.
Waist measurements also decreased by about 9 to 14 centimeters in users of "Ribobatide", compared to only 2.5 centimeters in the placebo group.
The most common side effects were:
Nausea.
Vomiting.
Diarrhea.
It affected about half of the participants in the lower dose, and about two-thirds of the participants in the higher dose, but most cases were mild or moderate.
Despite the encouraging results, the researchers cautioned about some limitations, including that the 48-week treatment period may not be sufficient to observe the full effect of the drug, and that the participants were relatively young, which may limit the generalization of the results to older adults who are overweight or obese.
The drug is currently being tested directly against semaglutide in another trial involving about 1,200 people in Britain and several other countries.
what is your opinion on this news ?do let us know in the comments on tha comment box
if you liked this news article please share on friends & family & don't forget to follow on website & social media


